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Gang Li1†, Tianbo Jin2†, Hongjuan Liang1, Yanyang Tu3, Wei Zhang4, Li Gong4, Qin Su4,5* and Guodong Gao1*Abstract: Skewed X-chromosome inactivation (SXCI) was found in some apparently healthy females mainly from
Western countries. It has been linked to development of ovarian, breast and pulmonary carcinomas. The present
study aimed to observe the SXCI frequencies in apparently healthy Chinese females and patients with esophageal
carcinoma. DNA was extracted from the peripheral blood cells from 401 Chinese females without a detectable
tumor and 143 female patients with esophageal carcinoma. Exon 1 of androgen receptor (AR) gene was amplified,
and the products of different CAG alleles were resolved on denaturing polyacrylamide gels and visualized after
silver staining. The corrected ratios (CR) of the products before and after HpaII digestion were calculated. As to the
healthy females, when CR ≥ 3 was used as a criterion, SXCI was found in two (4.3%) of the 46 neonates, 13 (7.8%) of
the 166 younger adults (16–50 years) and 37 (25.7%) of the 144 elderly females (51–96 years), with the frequency
higher in the elderly subjects than in the two former groups (P < 0.05). When a more stringent criterion (CR ≥ 10)
was used, SXCI was found in one (2.2%), two (1.2%) and 16 (11.1%) of the subjects in the three age groups,
respectively, itsfrequency being higher in the elderly than in the younger age groups (P < 0.05). Occurrence of SXCI
was detected in both the patients and controls at similar frequencies. However, the phenomenon, as defined as
CR≥ 3, was more frequent in the patients aging <40 years (35.7%) compared to the corresponding reference group
(7.6%, P = 0.006). When CR≥ 10 was adopted, the frequencies were 7.1% and 1.2%, respectively. Their difference did
not attain statistical significance (P = 0. 217). SXCI also occurs in apparently healthy Chinese females, and is
associated with age. It may be considered as a predisposing factor for the early development of esophageal
carcinoma.
Virtual slides: The virtual slide(s) for this article can be found here http://www.diagnosticpathology.diagnomx.eu/
vs/1542364337927656
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predispositionIntroduction
In female mammals one of the two X chromosome is
inactivated in early embryonic life. Females are therefore
mosaics for two cell types, cells with the maternal X
chromosome (Xm) as the active one, and cells with the
paternal X chromosome (Xp) as the active X one [1,2].
Theoretically, the ratio of the inactive paternal X-linked
allele to the inactive maternal one should be 1:1, and
any significant deviation from the ratio is termed as* Correspondence: suqinpathology@yahoo.com.cn; gguodong@fmmu.edu.cn
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reproduction in any medium, provided the orskewed X-chromosome inactivation (SXCI) [3,4]. The
Lyonization ratio (inactive Xp/inactive Xm) of a large
population of females follows a Gaussian distribution
pattern in which SXCI is a statistically rare event [5].
SXCI was incidentally observed when Vogelstein and
his colleagues were establishing a clonality assay based
on the human androgen receptor (AR) gene polymerase-
chain reaction (PCR) [3]. The phenomenon has been ob-
served and SXCI frequencies varied from 17% to 65% in
apparently healthy females as revealed by several surveys
from Western countries [5-12]. While its incidence was
found to increase with age [5-12], some groups failed to
prove the association [13,14]. Yet, up to date little is
known about whether there is such an association in ap-
parently healthy Chinese females or not.his is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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breast [15-17], ovarian [18] and pulmonary carcinomas
[19], however, the clinical significance of SXCI are still
to be elucidated. Does the imbalanced inactivation of X
chromosomes in female somatic cells, as usually demon-
strated using peripheral blood sample, indicate an in-
creased risk of malignant solid tumours development?
To our knowledge, esophageal carcinoma (EC) ranks as
the tenth most prevalent malignant solid tumours in the
world, with marked regional variation and a particularly
high incidence in certain regions of China [20-22]. Albeit
current evidence suggests that inherited risks play a sig-
nificant role in esophageal carcinoma susceptibility, and
several molecular alterations have been found in esopha-
geal carcinoma [20,22], the underlying pathomechanisms
remain elusive. Thus, the present study described the
frequency of SXCI in apparently healthy Chinese females
and linked the phenomenon to early development of
esophageal carcinoma.
Subjects and methods
Subjects and DNA extraction
Peripheral blood was taken from 143 female patients
with esophageal carcinoma and 401 apparently healthy
females. The patients were admitted in Tangdu hospital,
Fourth Medical Military University in Xi’ an, China du-
ring the period from April 2003 to October 2010, with
all of the cases diagnosed as a primary esophageal car-
cinoma through endoscopy and/or surgical resection of
the tumour, and pathological examination. The patients
were 35 to 83 (median, 61) years old at diagnosis, with-
out a record of smoking or a family history of eso-
phageal carcinoma. Among them, 141 patients had
squamous cell carcinoma, and 2 had adenosquamous
carcinoma. Clinical stages were evaluated according to
the AJCC staging system [23], with 92, 13, 10, 16, 12
cases determined as stages I, IIA, IIB, III and IV, respect-
ively. A total of 401 apparently healthy females were
recruited from April 2003 to September 2010. They were
from 2 days to 96 (median, 62) years of age, without a
smoking history or any personal or family record of a
genetic or a neoplastic disease. Among them, 69 were
staff members of Tangdu Hospital who received regular
check-ups, 52 were healthy neonates (below 4 weeks of
age) born in the Department of Obstetrics, Tangdu Hos-
pital, and the remaining 280 were female patients admit-
ted to the Department of General Surgery of Tangdu
Hospital for surgical reasons other than a tumor or ge-
netic diseases. It was stated that 289 females of the 401
healthy ones, were previously assessed and reported on
[19]. A written informed consent was obtained from all
the subjects or their custodians, and we collected all
the blood samples from the patients before chemo-
therapy or radiotherapy. The protocol was approvedby the Medical Ethics Committee of the Fourth Military
Medical University.
Peripheral blood was taken from the elbow vein or the
head superficial vein, and treated immediately with an
anticoagulant containing sodium citrate (22 g/L) and so-
dium chloride (8.5 g/L). The samples were then stored
at −70°C before use. Genomic DNA was isolated from
the samples by using an extraction kit (Qiagene, Hilden,
Germany). DNA concentration and purity were deter-
mined by an ultraviolet spectrophotometer (Eppendorf,
Hamburg, Germany).
Principles of X-chromosome inactivation analysis
The analysis is based on differential inactivation of X
chromosomes of female somatic tissues and the CAG
short-tandem repeat (STR) polymorphism at the AR
gene exon 1 [24]. There are two HhaI and two HpaII re-
striction sites at the locus 100 bp upstream to the CAG
STR with a heterozygosity frequency of around 90%
[24,25]. X-chromosome inactivation is associated with
the methylation of these restriction sites. When these
sites are methylated, as on the inactive X chromosome,
the gene can not be transcribed, whereas when
unmethylated, as on the active X chromosome in fe-
males or on the male X chromosome, the gene can be
transcribed [18]. The digestion with methylation-
sensitive endonucleases, followed by PCR with primers
flanking these restriction sites and the highly poly-
morphic STR, can be used to distinguish between the
transcriptionally active and inactive X chromosome in
heterozygous female subjects.
In females with random X-chromosome inactivation,
the amplification products from both alleles should be
equal, with a ratio of approximately 1:1. In the neo-
plastic tissues most of which originate from single cell
clones [19], the ratio changes markedly compared
with the surrounding normal tissues. The nonrandom
X-chromosome inactivation has been used in the descrip-
tion of clonality status of lesions with undetermined nature
[26,27]. Meanwhile, a remarkable deviation of the ratio has
been observed in apparently non-neoplastic cell popula-
tions, such as peripheral blood cells of some females, which
is defined as SXCI [3,4].
Analysis of skewed X chromosome inactivation (SXCI)
DNA was digested by mixing 10 μL (1 μg) of sample
DNA with 0.5 μL of HpaII (10 U/μL; Promega, Madison,
WI, USA), 2 μL of 10 mol/L reaction buffer, 0.2 μL of 10
g/L bovine serum albumin and 7.3 μL of deionized
water. The mixture was then incubated at 37°C for 4 h
and the reaction was terminated by incubation at room
temperature for 30 min as suggested by the manufac-
turer. Nested PCR was conducted as described pre-
viously [19]. A negative, water-blank control was always
Figure 1 Representative data of AR gene exon 1 amplification
products of two subjects (A and B) with CAG STR
polymorphism. +, with HpaII digestion; -, without HpaII digestion;
M, DNA marker, the upper and lower bands representing positions
of 300 and 200 bp, respectively.
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was shown to be positive, the reaction was repeated
for the whole batch. The reaction fidelity of HpaII di-
gestion was guaranteed by parallel negative controls
with the enzyme omitted from the reaction mixture.
In addition, the whole assay was carried out twice in
independent series.
Amplification efficacy was demonstrated through elec-
trophoresis on 2% agarose gels. The amplification pro-
ducts with 4 μL for each were mixed with the same
volume of loading buffer (1 g/L xylene cyanole, 1 g/L
bromophenol blue, in formamide), loaded onto the 10%
polyacrylamide gel containing 8 mol/L urea, resolved
through electrophoresis with the Mini-VE system
(Amersham Biosciences Corp., San Francisco, CA) at a
voltage of 80 v for 8 h, and then visualized after silver
staining as described previously [25]. For the samples
whose allelic differences at the CAG STR were small
(one or two repeats), a longer gel (26-cm long and 0.75-
mm thick) was used for the resolution with the SE660
system (Amersham). The results were recorded, and the
intensities of the products from both alleles were ana-
lyzed by using an image-analyzing system (LabWorks
3.0, UVP, Cambridge, UK).
In order to avoid the interference of possible preferen-
tial amplification of one of the alleles, we used the
corrected ratio (CR) to evaluate the X-chromosome in-
activation pattern by comparing the allelic difference of
a sample before and after HpaII digestion. CR was de-
rived by dividing the ratio of the upper-band intensity to
the lower-band intensity of the sample after digestion by
that of the same sample before digestion. If CR was <1,
the reciprocal value was considered. In the present
study, CR ≥ 3, which indicated the expression of the
same allele in above 75% of the cells examined, was used
to define SXCI. In addition, we also used CR ≥ 10 as a
more stringent criterion for defining SXCI.Statistical analysis
Statistical analysis was performed using an SPSS package
(Version 13.0; SPSS Inc., Chicago, Illinois) for Windows.
The likelihood ratio test was performed to determine
the difference SXCI frequency among various age
groups. The χ2 test was also used for comparison of ca-
tegorical variables. A P value of <0.05 (two-tailed) was
considered statistically significant.Figure 2 Representative data of X-chromosomal inactivation
patterns in subjects, with SXCI in samples from subjects A
(CR = 14, >10), B (CR = 19, >10) and C (CR = 4, >3) and without
SXCI in the sample from subject D (CR = 2.1, <3). M, DNA marker,
with the upper and lower bands at positions of 300 and 200
bp, respectively.Results
Amplification for AR gene exon 1 was successful in all
samples from the subjects. Among the 401 healthy fe-
males, 356 (88.8%) were shown to be polymorphic at the
CAG STR (Figure 1), and hence informative for X-
chromosome inactivation analysis. The ages of theinformative cases ranged from 2 days to 96 years, with a
median age of 63 years.
Both CR ≥ 3 and CR ≥ 10 were used as criteria for
SXCI to describe the X-chromosomal inactivation
skewing in the subjects (Figure 2). Among them, 52
(14.6%) were found to have a CR value more than or
equal to 3 and 19 (5.3%) had a CR value more than or
equal to 10. Frequencies of SXCI (CR ≥ 3) in various age
goups were determined, being 4.3% (2/46), 4.9% (3/61),
9.5% (10/105), 10.8% (7/65) and 38.0% (30/79), respect-
ively, in the neonates and those who aged 16 to 30, 31 to
50, 51 to 70 and 71 to 96 years. For age-matched
comparision to the patient groups as described below,
the 356 informative healthy subjects were further di-
vided into three age groups including neonates (2 to 28
days of age; median, 19days; n = 46), younger adults (16
to 50 years of age; median, 41 years; n = 166) and the
elderly subjects (51–96 years of age; median, 73 years;
n = 144). When CR ≥ 3 was taken as the criterion, SXCI
frequencies were 4.3% (2/46), 7.8% (13/166) and 25.7%
(37/144), respectively, in the neonate, younger adult and
Table 1 Skewed X-chromosomal inactivation frequencies
in esophageal carcinoma patients of various age ranges












Patients ≤40 14 5 (35.7) 0.006 1 (7.1) 0.217
Controls 170 13 (7.6) 2 (1.2)
Patients >40 120 8 (6.7) 0.301 6 (5.0) 0.940
Controls 115 12 (10.4) 6 (5.2)
Patients 35-83 134 13 (9.7) 0.757 7 (5.2) 0.214
Controls 16-83 285 25 (8.8) 8 (2.8)
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SXCI was found in only one neonate (2.2%), two (1.2%)
younger adults and 16 (11.1%) elderly females. SXCI fre-
quency was significantly associated with age (P < 0.001),
and the frequency in the elderly was higher than that in
younger adults (P < 0.05) or in the neonates (P < 0.05)
whether CR ≥ 3 or CR ≥ 10 was used as a criterion. SXCI
appeared to be more frequent in the adults than in neo-
nates, when CR ≥ 3 was used as the criterion (4.3% and
16.1%, P = 0.041) (Figure 3), while the difference between
neonates and the younger adults without a detectable
cancer did not attain statistic significance, whether using
CR ≥ 3 or CR ≥ 10 as the criterion.
Among the 143 patients with esophageal carcinoma,
134 were shown to be polymorphic at the CAG STR,
and thereby informative for X-chromosomal inactivation
analysis. Their ages at diagnosis ranged from 35 to 83
years, with their median being 63 years. No significant
difference was found between the polymorphism fre-
quencies for the cancer patient and control groups
(93.7% vs 88.8%, P > 0.05). With these data combined,
the frequency of CAG STR polymorphism was 90.1%
(490/544), being similar to that from other authors
[5,7,12,13,15,18,19,28-32].
SXCI frequeny was evaluated for patients with esopha-
geal carcinoma, and compared to that of the referenc
group (Table 1). When CR ≥ 3 was adopted to determine
SXCI, the frequencies were 9.7% and 8.8%, respectively.
When CR ≥ 10 was adopted, the frequencies were 5.2%
and 2.8%, respectively. The differences were not signifi-
cant (P > 0.05). However, the frequency in the patients
aging ≤40 years (35.7%) was found to be higher than that
in the corresponding references without a detectable
cancer (7.6%) as SXCI defined as CR ≥ 3 (P = 0.006).
When CR ≥ 10 adopted, the frequencies were 7.1% and
1.2%, respectively, and their difference did not attain
statistical significance (P = 0. 217). In the patients and
references beyond 40 years, the excessive skewing, as de-
fined by CR ≥ 3 and CR ≥ 10, were observed in 6.7%,Figure 3 Incidence of SXCI (CR ≥ 3) in normal females from
three age groups.10.4% and 5.0%, 5.2% of the subjects, respectively. No
significant difference was found between these two
groups (P > 0.05).
The average ages of the subjects with and without
SXCI were determined for both groups (Figure 4).
Whether CR ≥ 3 or CR ≥ 10 was taken as the criterion,
average age of the apparently healthy female sujects with
SXCI was more than 10 years older than that of those
without SXCI (P < 0.05). In contrast, average age of the
cancer patients with SXCI was more than 16 years youn-
ger than that of those without SXCI (P < 0.01; Figure 4).
The relationship between SXCI and clinical stages of
the cancer was assessed. With the criterion of CR ≥ 3
adopted, the frequencies for the cases of stages I, IIA,
IIB, III and IV were 8.0% (7/88), 20.0% (2/10), 10.0% (1/10),
13.3% (2/15), and 9.1% (1/11), respectively. There was no
significant difference among them (P > 0.05).
Discussion
SXCI was described in 1987 during a clonality assay
based on AR gene polymorphism using tissue samples
[3]. After then, the phenomenon was also observed inFigure 4 Average ages of the esophageal carcinoma patients
and references with SXCI defined by CR ≥ 3 (filled bar) and
without SXCI (empty bar). Their standard deviations denoted on
each bars. The differences in both the control and patient groups
are statistically significant, with their P values below 0.05 and
0.005, respectively.
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inactivation patterns in apparently healthy American fe-
males by Gale et al. [4] and Busque et al. [5]. Its occur-
rence was associated with age, with SXCI (CR ≥ 3)
frequencies being estimated to be 8.6%, 16.4% and
38.0%, respectively, in neonates, young (28 to 32 years)
and elderly (≥60 years) female adults [5]. Data from se-
veral other groups confirmed the SXCI association with
age [5-12,32], while some authors failed to approve it
[13,14]. In the present study, SXCI was also observed in
peripheral blood cells from apparently healthy Chinese
females without a detectable tumor. The SXCI (defined
by CR ≥ 3) frequencies were estimated to be 4.3%, 7.8%
and 25.7%, respectively, in the neonates, younger adults
(16 to 50 years) and the elderly (beyond 50 years)
(Table 2). The present study shows that SXCI also oc-
curs in neonates, albeit infrequently, and provide furthur
evidence for the link of SXCI to ageing.
The mechanism of SXCI is largely unknown. It is be-
lieved that a large proportion of SXCI cases result from the
selection for, or against, alleles on the active X chromo-
some. Such selection may depend on the expression of the
gene as well as its interactions with other genes [33]. SXCI
may also occur when the size of the pool of the embryonic
precursor cells undergoing X-chromosome inactivation is
too small to avoid stochastic variation [33]. This can
explain, at least partly, the existence of SXCI in some
neonates. In addition, SXCI may be attributable to rela-
tively small selective advantages such as X-chromosome
rearrangements and mutations in X-linked genes [34,35].
When considering its pathogenic pathways, the








Lau et al. [8] Canadian 27 35-50 33
Busque et al. [5] American 295 0-96☆☆ 17
Gale et al. [6] English 174 17-96 38
Tonon et al. [7] Italian 68 25-32, ≥75 23
Knudsen et al. [11] Norwegian 80 19-90 65






Racchi et al. [13] Italian 166 8-94 30





1 005 0, >13 25※
Present study Chinese 356 0-96 15
* Not mentioned in the study; ** The likelihood ratio test; ※ skewed to the extent of
§allelic ratios: ≥ 4:1 or 80% predominant expression of one allele.
☆ The χ2 test; ☆☆ age constitution: neonates (n = 162); younger adults (25–32 y) (nX-chromosome inactivation of precursor cells in early
embryogenesis, is considered to be inborn SXCI,
whereas the skewing that occurs during adulthood and
is prevalent with age, is designated as acquired SXCI [5].
The former occurs at a low frequency (<5%) in normal
females and is responsible for the neonate SXCI cases,
although its significance is unknown. The latter, we be-
lieve, occurs due to the selection or structural alterations
in X chromosomes.
Our data also suggests that SXCI occurs less fre-
quently in the apparently healthy females in China (15%,
with CR ≥ 3 as the moderate criteria) than in those in
Western countries, as listed in Table 2. The reason for
this difference is unknown. Ethnic genetic variation may
be one explanation. Minor differences in some genomic
structures including STR and single-nucleotide poly-
morphism (SNP) sites among different ethnic groups
have been reported [36,37], which may modulate the
process of SXCI occurrence in females. In the present
study, 356 informative cases were examined, and the re-
sults showed that their ages, ranging from 2 days to 96
years, followed a Gaussian distribution. The SXCI fre-
quency, as provided herein, can reflect the overall status
in healthy Chinese females.
While SXCI occurrence was associated with the auto-
immune diseases including autoimmune thyroid diseases
[38-40], and systemic sclerosis [41], this phenomenon
has been linked to development of a few of malignant
solid tumours [33] in females. In 1999, Buller et al.
reported that patients with invasive ovarian cancer had
an increased frequency of SXCI compared to those with-
out a detectable fully malignant ovarian tumor [18]. In aage ranges and ethnic groups
SXCI (CR ≥ 3) incidences of healthy females
of various age ranges (%)
P-value
0 25- 32 16- 50 35- 50 51- 70 ≥60 ≥75 71- 96
* * * 33 * * * * *
9 16 * * * 38 * * <0.0001**
* * 22 * * * 6 * < 0.0001*
* 17 * * * * 45 * < 0.02☆
* 0.034**
* 0.0008**
* 23 26 * * 37 40 * >0.05**
* <0.0001**
* 0.008※※
4.3 6.1 7.8 9.4 10.8 27.6 40.6 38.0 0**
>70:30 or <30:70; ※ ※ F test.
= 67); older adults up to 60 y (n = 66).
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was shown to be markedly increased in young patients
(≤45 years) with breast cancer (13%) compared to that of
the control group (1%) [16]. The similar phenomenon
was also observed in familial breast cancer patients with-
out a detectable BRCA-1 or BRCA-2 mutation [17].
Additionally, it is well known that esophageal carci-
noma (EC) is one of the most prevalent cancers in the
world with characteristic regional variation. In the past 4
years, several genome-wide association studies (GWAS)
in Chinese populations [42-44] and Japanese individuals
[45] revealed a few of functional SNPs, which encode
metabolic enzymes for carcinogens associated with en-
hanced EC risk. Recently, another GWAS and genome-
wide gene-environment interaction analysis of EC was
also carried out in 2,031 affected individuals (cases) and
2,044 controls with independent validation in 8,092
cases and 8,620 controls in the Chinese population [20].
Similar to the previous studies [42-45], the GWAS con-
firmed a few of new EC susceptibility loci and the ge-
netic contribution to EC through interaction with
enviroment [20], However, all the authors were obliged
to convery that EC was such a complex disease, and the
direct genetic contribution to EC risk factors and its
relationto other factors should be discussed more deeply
[42], and more studies are needed to explore the under-
lying mechanisms.
In the present study, SXCI (CR ≥ 3) frequency was
determined to be as high as 35.7% in young patients
(≤ 40 years) with esophageal cancer, being significantly
higher than that in the corresponding control group
(7.6%), though the size of subjects detected was rela-
tively small. Moreover, the average age at diagnosis in
the cancer patients with SXCI was 16 years younger
than that in the patients without SXCI. In the previous
study of our group, SXCI was also observed more fre-
quently in the female patients with lung cancer below
50 years (CR ≥ 3, 35.7%; CR ≥ 10, 7.9%) compared to
that in the reference group (CR ≥ 10, 7.6%; CR ≥ 10,
1.2%). The cancer patients with SXCI, whether defined
as CR ≥ 3 or CR ≥ 10, were 10 years younger on aver-
age than those without SXCI. Based on the data, SXCI
was considered to be a predisposing factor for the
early onset of lung cancer [19]. For this reason,
follow-up was conducted after the survey for all of
the 265 apparently healthy women recruited into the
reference group in March 2005. Among the 27 sub-
jects whose CR values were determined to be ≥3, a
34-year-old female (CR = 9.0) was diagnosed as pul-
monary squamous cell carcinoma in April 2006 and
died in July 2006, with the histological type being squa-
mous cell carcinoma and the clinical stage being stage
IV, while no malignancy was detected for the others
(unpublished data).Conclusion
In conclusion, our data prove that SXCI is a predispo-
sing factor also for the early development of esophageal
carcinoma. We consider that SXCI may be used as a
useful parameter to assess susceptibility of females to
several solid tumours, including the early development
of esophageal carcinoma.
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